Aptamers for Serum Biomarker Detection in Pancreatic Cancer: The Glycan Gap and the Evidence Gap

Pancreatic ductal adenocarcinoma (PDAC) is lethal largely because it is diagnosed after it has spread, and the only blood marker in routine use, carbohydrate antigen 19-9 (CA19-9), is a fucosylated glycan whose synthesis depends on polymorphic fucosyltransferases. Aptamers - short single-stranded oligonucleotides selected entirely in vitro - have been proposed for two decades as the recognition element that could make PDAC detectable in serum. Here we assess that proposal against the literature of the past three years. Three conclusions emerge. First, the analytical problem is largely solved: electrochemical, plasmonic, transistor-based and amplification-coupled aptasensors now reach femtomolar to attomolar limits of detection, two to four orders of magnitude below the concentration of every circulating PDAC analyte. Second, the binding problem is not solved in the place where it matters: aptamers are selected against protein epitopes, whereas the clinically validated PDAC marker is a carbohydrate, and the glycan-recognition reagents that would close this gap remain scarce. Third, the evidence problem is untouched: almost all published aptasensors stop at case-control comparison against healthy donors, a design that cannot address the benign pancreatic diseases, diabetes and jaundice that dominate the differential diagnosis, and that inflates positive predictive value in a population where prevalence is 1-2%. We set out the analyte, recognition, selection, transduction and evidence requirements for an aptamer test that could plausibly change how PDAC is found, and argue that the field’s next advance will come from assay architecture - logic-gated, multi-analyte, single-vesicle measurement - rather than from another order of magnitude in sensitivity.